The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis
Open Access
- 1 November 1987
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 20 (5) , 753-758
- https://doi.org/10.1093/jac/20.5.753
Abstract
The efficacy of ciprofloxacin was compared with that of vancomycin in the rabbit model of methicillin-susceptible Staphylococcus aureus endocarditis. Animals were treated with ciprofloxacin, 25 mg/kg iv every 8 h or vancomycin, 17.5 mg/kg iv every 6 h, for 3, 6, or 9 days. Both drugs were found to be equally effective in the therapy of this infection, but the degree of reduction in bacterial counts was less than expected on the basis of previous studies. Additionally, resistance to ciprofloxacin in the test strain of S. aureus was seen to emerge in 12.5% of animals that received the drug. This raises concern about the use of ciprofloxacin as a single agent in the therapy of humans with serious systemic S. aureus infections.Keywords
This publication has 5 references indexed in Scilit:
- Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditisAntimicrobial Agents and Chemotherapy, 1987
- Dose ranging study and constant infusion evaluation of ciprofloxacinAntimicrobial Agents and Chemotherapy, 1986
- Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1986
- Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteriaAntimicrobial Agents and Chemotherapy, 1984
- Serum Dilution Test for Bactericidal Activity. I. Selection of a Physiologic DiluentThe Journal of Infectious Diseases, 1977